Mineralocorticoid receptor (MR) blockade is effective in reducing total mortality and the incidence of heart failure in patients with systolic left ventricular dysfunction (SLVD) associated with chronic heart failure or post myocardial infarction.
Introduction
The Randomized Aldactone Evaluation Study (RALES) showed that the mineralocorticoid receptor (MR) blocker, spironolactone, reduced mortality by 30% and heart failure hospitalisations by 35% in patients with severe heart failure treated with standard therapy, including an angiotensin-converting enzyme (ACE) inhibitor, diuretic + digoxin and/or a β adrenergic receptor blocking agent (BB). 1 This study provided important proof of principle that MR activation is of pathophysiological importance in patients with severe heart failure due to systolic left ventricular dysfunction (SLVD).
Further proof of the importance of MR blockade comes from the eplerenone post acute myocardial infarction (MI) survival and efficacy study (EPHESUS) . In this study, eplerenone, a selective aldosterone blocker, was shown to reduce total mortality by 15%, as well as the combined endpoint of cardiovascular mortality/cardiovascular hospitalisation by 13%, when administered at a mean of 7.3 days post-infarction to patients with evidence of SLVD and signs of heart failure. 2 This improvement occurred on top of standard therapy, as the majority of these patients were treated with both an ACE inhibitor (ACE-I) and a BB. It has, however, been difficult to determine the precise mechanisms by which MR blockade translates into improved survival in patients with heart failure due to SLVD or post-infarction SLVD treated with standard therapy including an ACE-I and a BB.
MR blockers are known to promote sodium excretion 3 and the combination of spironolactone and an ACE-I has been shown to be more effective than either alone in causing natriuresis. 4 However, it appears unlikely that the benefits of low-dose spironolactone (mean dose = 26 mg/day in RALES) and eplerenone (mean dose = 43 mg/ day in EPHESUS) are attributable solely to their diuretic effects. 1 In the RALES study, spironolactone had no effect on blood pressure (BP), heart rate, or serum creatinine. There was a small but significant effect on serum potassium in those patients randomised to placebo versus spironolactone, (4.37 vs. 4.54 mEq/L) respectively, at the end of the mean two-year follow-up period. However, the sodium retention score, a clinical composite score evaluating volume overload, although increased in New York Heart Association class IV as compared with class III heart failure patients, was not different between those randomised to placebo or spironolactone. 5 In EPHESUS, there was also a small but significant effect on serum potassium in patients randomised to placebo compared with eplerenone at one year (4.5 vs. 4.6 mmol/L) but no change in body weight. 2 Thus, it can be postulated that the effects of MR blockers on mortality in patients with chronic heart failure or post-infarction SLVD are likely to be related to the beneficial effects of preventing MR activation in the myocardium, vasculature, and nervous system,resulting in a reduction in myocardial Heart failure and the renin-angiotensinaldosterone system Pitt and vascular fibrosis, [6] [7] [8] improvements in autonomic imbalance, [9] [10] [11] increased fibrinolysis 12, 13 and improvements in endothelial function. 14 Consonant with these proposed sites of action of MR activation, are data indicating the presence of MR in cardiac myocytes, vascular smooth muscle cells, and endothelial cells. 15, 16 Additionally, aldosterone-generating enzymes have been demonstrated in the myocardium and the vasculature, [17] [18] [19] [20] suggesting that these organs have the capacity to synthesise aldosterone and respond to it, independent of the adrenal gland.
Aldosterone as a pathophysiologic mediator of vascular and myocardial disease
The level of plasma aldosterone has been reported to be an important predictor of survival in patients with heart failure. 21 Current therapy for heart failure due to SLVD, including standard doses of ACE-I, angiotensin receptor blockers, their combination, and/or a BB, may not, however, suppress plasma aldosterone levels over the long term. [22] [23] [24] [25] Increased production of aldosterone can be mediated either directly or indirectly by factors other than angiotensin II (Ang II), including potassium, 26 ACTH, 26 endothelin, 27, 28 and vasopressin. 29 Furthermore, studies in angiotensinogen knockout mice have shown that adrenal aldosterone production can occur in the complete absence of Ang II. 30 Thus, Ang II, although important for the production of aldosterone, is not essential. Increased plasma and/or tissue levels of aldosterone have the potential to modulate other paracrine loops. For instance, aldosterone has been shown to increase tissue ACE 31 endothelin, 32 and norepinephrine, 33 resulting in a number of vicious cycles. Inhibition of aldosterone can be hypothesised to exert effects on these latter pathways and may represent a key mechanism by which MR blockade may modulate and preserve vascular homeostasis. An increase in serum aldosterone does not, however, appear to be necessary for the beneficial effects of either spironolactone or eplerenone. For example, in streptozotocininduced diabetic rats, spironolactone has been shown to lower systemic BP to control values, despite the fact that serum aldosterone levels were below normal. 34 Similarly, eplerenone has been shown to be effective in reducing BP, left ventricular mass, and the incidence of microalbuminuria in patients with essential hypertension and left ventricular hypertrophy in whom serum aldosterone levels were normal. 35 The explanation for the effectiveness of MR-blocking agents in situations with normal or subnormal serum aldosterone levels is as yet unclear, but may relate to an increase in tissue aldosterone concentrations in conjunction with a relatively high sodium intake, independent of serum levels, or most likely to the fact that the MR can be occupied and activated by cortisol as well as by aldosterone. Under normal circumstances, the MR is protected from occupancy by cortisol by the enzyme 11β-HSD2, which degrades cortisol to corticosterone. The latter cannot occupy or activate the MR. It is conceivable that, under conditions associated with increased oxidative stress or hypoxia, especially in non-epithelial MR such as in the vascular wall or the heart, 11β-HSD2 may be down-regulated and the receptor activated by cortisol. 36 Understanding the role of aldosterone and activation of the MR by aldosterone or cortisol may therefore provide insights not only into heart failure due to SLVD, but possibly to a wide range of cardiovascular diseases, including atherosclerosis, hypertensive cardiovascular disease, and renal disease.
Inflammation: a consequence of activation of the MR
There is emerging evidence that activation of MR results in pro-inflammatory effects that are vasculotoxic, while MR blockade prevents these effects. In studies in the salt-fed spontaneously hypertensive rat stroke prone model (SHRSP), Rocha et al. showed that MR blockade markedly reduces the incidence of stroke and the development of renal injury, as evidenced by a reduction in proteinuria and renal microvascular lesions, independent of alterations in systemic haemodynamics. 37, 38 Similarly, in double transgenic rats harbouring both the human renin and angiotensinogen genes (dTGR), a model that has been associated with Ang II excess, vascular and myocardial injury, MR blockade reduced collagen deposition and inflammation in the myocardium, concomitant with the down-regulation of the transcription factorsnuclear factor-kappa β (NF-κβ) and activator protein-1 (AP1). 39 At least in the aldosterone infusion model, the inflammatory effects in the vasculature appear to be related to free radical generation, as these effects of aldosterone (proteinuria, fibrinoid necrosis of blood vessels, and renal tubular damage) could be prevented by dimethylthiourea, a hydroxyl radical scavenger, at a dose that had no significant effect on BP. 40 The importance of MR blockade in reducing oxidative stress was recently demonstrated in a rabbit model of dietary hyperlipidaemia, a model not associated with elevations of circulating aldosterone levels. Administration of the specific MR blocker, eplerenone, in this model significantly decreased NADH/NADPH oxidase-dependent free radical generation within the vascular wall and improved endothelial-dependent vasodilatation. 41 Independent studies, in a rat model of heart failure with spironolactone, support and extend these findings by demonstrating a reduction in p22phox subunit mRNA levels. 42 These experimental studies support the findings of an improvement in endothelial function and nitric oxide ( G NO) availability by MR blockade in patients with chronic heart failure due to SLVD treated with an ACE-I. Interestingly, treatment of these patients with an MR blocker was also associated with decreased conversion of angiotensin I to Ang II, consistent with an ACE-I-like effect. 14 feedback loop. 31 The effects of MR activation on pro-inflammatory free radical pathways and, consequently G NO availability, may also have important implications for understanding its role in saltsensitive hypertension. There is increasing data to suggest that G NO suppresses the production of aldosterone in the adrenal gland and, conversely, inhibition of G NO formation increases the production of aldosterone. [43] [44] [45] Although the effect of modulating G NO availability on the vascular and myocardial production of aldosterone or activation of the MR by cortisol is as yet unknown, it can be postulated that cardiovascular risk factors, such as smoking, hypercholesterolaemia, diabetes mellitus and ageing, all of which are associated with inadequate G NO availability, either because of increased destruction and/or decreased synthesis, would tend to increase aldosterone levels in the plasma and/or the vascular wall or cortisol occupancy and activation of the MR, thereby creating a series of vicious cycles involving Ang II, endothelin, norepinephrine and activation of the NF-κβ and AP1 signalling pathways. The association of excess sodium with aldosterone-induced targetorgan damage may also be explained by this mechanism. Maintenance of normotensive Wistar-Kyoto rats on a high sodium intake for eight weeks decreased plasma renin and aldosterone levels, but increased cardiac aldosterone synthesis,AT 1 -receptor activity, and ventricular hypertrophy without an increase in systemic BP. 46 Dietary salt has also been shown to increase the production of ROS in the plasma and the urine of Dahl salt-sensitive rats, resulting in a decrease in urinary cyclic GMP levels, a decrease in renal function, and the development of hypertension. 47 Salt may independently down-regulate endothelial G NO synthase, resulting in diminution of G NO formation. 48 These findings, in conjunction with the increased expression of local aldosterone synthesis, MR, and the Ang II type I receptor with dietary salt loading, may help in understanding the potential synergistic effects of aldosterone and salt in salt-sensitive hypertension and possibly in other cardiovascular diseases such as diastolic dysfunction. 46, 49 The above concepts may also explain many of the apparently diverse non-renal effects of MR blockade. For example, the effects of MR blockers on myocardial and vascular fibrosis in experimental models of hypertension appear to be secondary to inhibition of micro-vascular inflammation, as a result of activation of inflammatory signalling molecules, such as osteopontin, 50 and growth factors, such as transforming growth factor-β 51 and epidermal growth factor, 52 which, in turn, have been related to Ang II, endothelin, and oxidative signalling pathways. These effects on vascular and myocardial fibrosis, that have been known for years, have important implications for vascular and ventricular remodelling, as well as hypertrophic states. 53, 54 Aldosterone levels are also correlated with increased plasminogen activator inhibitor-1 (PAI-1) levels and the ratio of PAI-1/ tissue plasminogen activator (tPA). 55 PAI-1 levels are also related to increased oxidative stress and reduced G NO availability. 56 The effect of MR blockers on PAI-1/tPA has important implications not only for preventing the occurrence of MI and sudden cardiac death, but also for fibrosis and atherosclerosis. 57
MR blockade as a therapeutic strategy
Sudden cardiac death Increased heart rate variability and baroreceptor dysfunction are known to be important independent predictors of sudden cardiac death and, in part, reflect an imbalance in autonomic tone. 58 MR blockers have been shown to improve baroreceptor function and heart rate variability, [9] [10] [11] 59 while mineralocorticoids, especially in conjunction with salt, increase QT dispersion. 49 Recently, baroreceptor function and heart rate variability have been linked to G NO availability. 60 Thus, the effects of MR blockers on G NO availability may partially explain their beneficial effects on sudden cardiac death. The effects of MR blockers on norepinephrine uptake by the myocardium, 33 although not as yet definitively linked to oxygen free radical production, nevertheless may be related, as it has been shown that G NO has important effects on norepinephrine release from peripheral sympathetic neurones and the adrenal medulla. 61 The beneficial effects of MR blockers on sudden cardiac death may, however, also relate to their effects on myocardial fibrosis and to an increase in serum and/or tissue potassium and magnesium as a consequence of their renal effects.
Left ventricular remodelling post-MI and in chronic heart failure
In experimental MI, the administration of eplerenone results in a reduction in collagen levels and fibrosis in the non-infarcted myocardium, 62 without compromise of myocardial scar formation. Two recent studies, using either spironolactone or potassium canrenoate, a metabolite of spironolactone in post-MI patients, resulted in decreases in aminoterminal propeptide type III procollagen (PIIINP) and significantly smaller left ventricular volumes. 63, 64 Similarly, MR blockers have been shown to improve ventricular remodelling in patients with chronic heart failure, due either to ischaemic or non-ischaemic cardiomyopathy. 65 Further proof of the importance of MR blockade can be seen from the results of EPHESUS. 2 In this trial, approximately 6,600 patients with acute MI, SLVD, and evidence of heart failure (except in those with diabetes mellitus, in whom only SLVD was required) were randomised to eplerenone, at a mean dose of 43 mg daily, or placebo post-infarction. Patients randomised to eplerenone had a significant reduction in all-cause mortality, and cardiovascular mortality, mainly due to a reduction in sudden cardiac death. Of importance was the finding, in patients on an ACE-I or Ang II type 1 receptor blocker and a BB, that eplerenone resulted in a significant 27% reduction in all-cause mortality. Patients on 'optimal' therapy post-infarction, including an ACE-I/ARB and a BB, aspirin, statin, and who were 
Essential hypertension
Both spironolactone and eplerenone have been shown to be effective in reducing both systolic and diastolic BP in patients with essential hypertension. 66, 67 Recently, eplerenone has been shown to be as effective as the ACE-I, enalapril, in reducing left ventricular mass and the incidence of microalbuminuria in patients with essential hypertension and baseline evidence of left ventricular hypertrophy by echocardiography, while, the combination of eplerenone and enalapril was significantly more effective than eplerenone alone. 35 
Atherosclerosis
Since MR blockade modulates inflammatory effects, improves endothelial function, and G NO availability, 41 it may be postulated to have beneficial effects on a variety of processes in atherosclerosis, such as the expression of adhesion molecules, monocyte activation, adhesion and migration into the vascular wall, oxidation of LDL cholesterol, platelet activation and adhesion, vascular smooth muscle cell migration and activation of metalloproteinases. Thus, MR blockade may have broad applicability as an anti-atherogenic strategy.
Other indications
Based on the information provided, MR blockers could play an important role not only in heart failure due to SLVD and essential hypertension with normal ventricular function, but also in diastolic heart failure, valvular heart disease, vascular stiffening with ageing, progression of renal dysfunction and diabetes mellitus. The ultimate test of the hypothesis that MR blockade breaks the vicious cycle induced by increased serum and or tissue Ang II, endothelin, norepinephrine, oxygen free radical availability, and is effective alone or in conjunction with an ACE-I or an AT 1 -receptor antagonist and a BB in a broad range of cardiovascular diseases will, however, require further direct experimental and clinical investigation in a variety of pathological disorders. Should this hypothesis prove correct, the impact on public health in relation to reduced morbidity, mortality, and costs associated with the treatment of hypertension, heart failure, atherosclerosis, stroke, MI, diabetes mellitus, and renal disease, could be profound. 
